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Abstract:  Atherothrombosis,  thrombus  formation  as  a  result  of  atherosclerotic  plaque 
rupture, is a major modern health problem, often underlying coronary artery disease, stroke, 
and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term 
therapy is warranted as a secondary prophylaxis of such events and their complications. Because 
of the importance of platelets’ involvement in the initiation and propagation of thrombosis, 
antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual 
antiplatelet therapy of aspirin plus clopidogrel – the current standard – has its benefits, but 
it also has its limitations with regard to its pharmacologic properties and adverse effects. For 
these reasons, within the last decade or so, the investigation of novel antiplatelet agents has 
prospered. Here, we review the main pathways through which platelets participate in acute 
thrombosis and the interruption of these pathways by using novel antiplatelet agents, including 
P2Y12  receptor  antagonists  (the  recently  approved  prasugrel,  the  probable  next-in-line 
ticagrelor, and others). The need for a more individualized patient therapy is evident; although 
most of the aforementioned pharmaceuticals have the potential to contribute to this, their 
clinical utility remains to be seen.
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Different classes of platelet-inhibiting drugs
Platelets have an established role in the pathogenesis of atherosclerosis-related 
diseases, including coronary artery disease (CAD), acute coronary syndromes 
(ACSs), and stroke. Rupture of an atherosclerotic plaque promotes the activation 
of platelets and initiates the coagulation cascade. Activation of platelets and their 
subsequent aggregation, which is amplified by various pathways, lead to thrombus 
formation at the site of vascular injury. Tissue hypoxia and irreversible damage in 
conditions such as myocardial infarction (MI) and ischemic stroke are rather due 
to an acute thrombus formed atop a ruptured atherosclerotic plaque than due to the 
stenosis caused by atherosclerosis.1 Thus, antiplatelet agents have been used in acute 
conditions of arterial thrombosis and as part of secondary prophylaxis to prevent 
recurrent thromboembolic episodes.
Acetylsalicylic acid (aspirin) was the first antiplatelet agent, which irreversibly 
inhibits the cyclooxygenase 1 enzyme in the arachidonic acid pathway through 
acetylation, thereby preventing the conversion of arachidonic acid into thromboxane 
A2 (TXA2) – a potent vasoconstrictor and platelet activator.2 Despite being used as a 
drug for more than 100 years, aspirin continues to play a dominant role in the treatment 
of cardiovascular diseases (CVDs) because of its ease of use and cost-effectiveness. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Long-term aspirin therapy brings about a 20%–25% odds 
reduction in the risks of subsequent MI, stroke, or vascular death 
among intermediate- to high-risk patients with atherothrombotic 
disease.3,4 However, its relatively low potency [producing only 
a partial inhibition of platelet aggregation (IPA)], some patients’ 
resistance to aspirin, and its gastrointestinal toxicity prompted 
the search for more potent, more consistent, and more specific 
platelet-inhibiting agents.1–3
Currently, two classes of antiplatelet drugs are used 
alongside aspirin. Clopidogrel, a thienopyridine adenosine 
diphosphate (ADP) receptor antagonist, on the basis of a 
12,562-patient study, CURE (Clopidogrel in Unstable angina 
to prevent Recurrent Events) trial in 2001, has become a 
standard part of dual antiplatelet therapy with aspirin, which 
is used for a longer term after an acute MI.5 Glycoprotein 
IIb/IIIa (GP IIb/IIIa) antagonists, such as abciximab, are 
used in high-risk patients before percutaneous coronary 
intervention (PCI).3 The limitations of clopidogrel – its 
delayed onset of action, interpatient variability in response 
to clopidogrel (including some patients’ outright resistance 
to it), and the irreversibility of its action – have encouraged 
the investigation of novel antiplatelet agents with satisfactory 
safety profiles and adequate efficacy.3,6,7
The process of platelet activation and aggregation involves 
multiple signaling molecules and their receptors, therefore 
allowing for many therapeutic targets. First, platelets adhere 
to the subendothelial proteins (ie, von Willebrand factor 
and collagens) exposed at sites of vascular injury. This is 
followed by intracellular signaling, with platelet activation 
and secretion of further mediators, which amplify and sustain 
the initial platelet response.8 In particular, activated platelets 
release ADP, serotonin, and calcium via degranulation, as 
well as synthesize thromboxane from arachidonic acid; 
thrombin, another key substance, is locally generated 
through the coagulation cascade.9,10 Platelet activation is 
propagated through blood-soluble agonists acting upon 
their respective platelet receptors: ADP via P2Y1 and P2Y12, 
thrombin via protease-activated receptor 1 (PAR1) and 
PAR4, and thromboxane via the thromboxane/prostanoid 
(TP) receptor.11 The final common pathway for all these auto-
crine and paracrine activation signals is GP IIb/IIIa-mediated 
platelet aggregation. Thus, in both physiologic hemostasis 
and pathologic states, platelets are recruited into the mass of 
a platelet – fibrin thrombus.9–11
The various classes of antiplatelet drugs act synergistically 
through complementary yet independent mechanisms, 
preventing platelet aggregation and thus acute thrombus 
formation. Currently available drugs and those under 
investigation target the thromboxane-induced (ie, aspirin and 
terutroban), ADP-induced (such as ticlopidine, clopidogrel, 
and prasugrel), and thrombin-induced (eg, SCH 530348 
and E5555) pathways of platelet activation and their final 
common pathway of GP IIb/IIIa (abciximab, eptifibatide, and 
tirofiban)-induced platelet aggregation.11–14 The processes of 
platelet adhesion, activation, and aggregation along with the 
targets of platelet-inhibiting drugs are shown in Figure 1.
All antiplatelet drugs, in addition to inhibiting acute 
arterial thrombosis, have the danger of interfering with the 
physiologic role of platelets in hemostasis. Thus, the range 
of adverse effects, particularly bleeding, is a major factor 
in evaluating the utility of the available and upcoming 
antiplatelet drugs and their combination regimens. In 
addition to the safety profile and drug efficacy, other factors 
to be taken into account when choosing from the available 
and developing antiplatelet drugs include the specificity to 
platelets, route of administration, reversibility of action, 
the onset of action, peak of effect, and its duration or 
wearing-off time (offset).
Blockade of ADP receptors  
of subtype P2Y12 – from the 
molecular level to the clinical  
utility of thienopyridines
The key role of ADP in the processes of platelet aggregation and 
thrombus formation has led to the development of antiplatelet 
drugs targeting the P2Y12 receptor. Activated platelets release 
ADP from their dense granules, which functions as a soluble 
positive feedback mediator that binds to the receptors (P2Y1 
and P2Y12) on the platelets’ surface. Both these purinoreceptors 
belong to the group of G-protein-coupled receptors, with P2Y1 
being coupled to Gq and P2Y12 to Gi; thus, each subtype of 
ADP receptor has a distinct intracellular signaling pathway.9,10 
Stimulation of the P2Y1 receptor and its Gq protein mobilizes 
intracellular calcium and triggers a change in the platelet shape 
and rapidly reversible aggregation.15 A signal through the 
P2Y12 receptor and its Gi protein results in reduced levels of 
cyclic adenosine monphosphate, amplification of the platelet 
response, stabilization of the resulting aggregates, and secre-
tion of further mediators from the granules.16 Although the 
coactivation of both purinoreceptors is necessary for normal 
ADP-induced aggregation, P2Y12 is considered the major 
platelet ADP receptor, and because of its more restricted 
expression, it has become an attractive therapeutic target of 
antithrombotic agents.9,13,17
The thienopyridine class of antiplatelets (ticlopidine, 
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inhibits the P2Y12 purinoreceptor throughout the lifespan of 
the platelet. Although currently clopidogrel is the dominant 
member, its modest platelet inhibition, delayed onset of 
action, and significant interpatient variability in response to 
clopidogrel (including some patients’ nonresponsiveness to 
the drug) paved the way for more potent and stable drugs.18 
Ticlopidine had been discovered before clopidogrel, but has 
been eclipsed because of its adverse hematologic side effects, 
including neutropenia and thrombotic thrombocytopenic 
purpura.3 The opposite is true of the third-generation 
thienopyridine, prasugrel – previously known as CS-747, 
LY-640315 – which has been approved by the United States 
Food and Drug Administration recently and has found a 
place in the latest recommendations of British and American 
institutions.19,20
All the orally administered thienopyridines are prodrugs, 
which require biotransformation into their active metabolites 
by fixed sets of hepatic cytochrome P450 (CYP) enzymes, in 
particular, the CYP3A4 isozyme. In contrast to clopidogrel’s 
esterase inactivation and two-step CYP-dependent activation, 
prasugrel has a more efficient and simpler metabolism, 
which requires only one reaction by the liver enzymes 
to yield its active metabolite.21,22 This difference in the 
metabolism of these thienopyridines translates clinically 
into different patient responses and drug interactions with 
these antiplatelet agents. Certain common genetic variants of 
CYP2C19 resulted in decreased levels of clopidogrel’s active 
metabolite, resulting in a lower platelet inhibition and most 
importantly a higher rate of major adverse cardiovascular 
events; on the other hand, prasugrel’s pharmacology and 
clinical efficacy were not found to be affected by CYP 
polymorphisms or by the concomitant use of CYP-inhibitory 
drugs. Other advantages of prasugrel include a faster onset 
of action and an approximately tenfold higher potency than 
clopidogrel.22–27
Prasugrel has been shown to be of particular benefit in 
patients with diabetes, especially those on insulin (30% 
relative risk reduction [RRR] in cardiovascular death, MI, 
or stroke [P , 0.001] and 37% RRR, respectively). Another 
look at the TRITON-TIMI 38 data with respect to diabetes 
status showed the reduction by prasugrel of the composite 
of CV death, MI and stroke noted in non-diabetic subjects 
(n = 10,462, 9.2% vs 10.6%, P = 0.02), was even more 
significant in those with diabetes mellitus (n = 3,146, 12.2% 
vs 17.0%, P , 0.001), especially those treated with insulin 
(n = 776, 14.3% vs 22.2%, P = 0.009).14,28 On the other 
hand, its dose should be adjusted for low-weight patients 
(,60 kg), and it should be rather avoided in the elderly 
($75 years) and in those with a history of stroke or transient 
ischemic attack because of an increased bleeding risk.29 Such 
recommendations are largely based on the results of the 
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Figure 1 Scheme of platelet adhesion, activation, and aggregation processes – showing the key players and sites of action of antiplatelet agents. Drugs at various stages of 
investigation appear in parentheses. 
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; ASA, aspirin; COX, cyclooxygenase; GP, glycoprotein; PAR, protease-activated receptor; PR, thromboxane/ 
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in Therapeutic Outcomes by optimizing platelet inhibition 
with prasugrel – Thrombolysis In Myocardial Infarction 38) 
on 13,608 patients with ACS undergoing planned PCI.30 It 
demonstrated the composite rate of death, MI, or stroke to 
be reduced by 19% and the rate of stent thrombosis to be 
halved in patients receiving prasugrel compared with those 
receiving clopidogrel. Although prasugrel had an increased 
efficacy, it also increased the risk of bleeding, especially in 
the aforementioned groups, including life-threatening hemor-
rhage and fatal bleeding.14,30
Although prasugrel is still under investigation, it has 
already found an official place in antiplatelet therapy through 
support from American and British institutions. In October 
2009, the United Kingdom’s National Institute for Health 
and Clinical Excellence recommended a limited use of 
prasugrel, in combination with aspirin, in three specific but 
sizeable subgroups of patients with ACS undergoing PCI: 
those undergoing immediate primary PCI for myocardial 
infarction with ST elevation (STEMI), those who had stent 
thrombosis during clopidogrel treatment, and those with 
diabetes mellitus.20 In November 2009, the American Col-
lege of Cardiology, the American Heart Association, and the 
Society for Cardiovascular Angiography and Interventions 
jointly released guidelines for the use of prasugrel in patients 
with STEMI once the coronary anatomy is known and PCI 
is planned.19
Ticagrelor – an overview of its 
pharmacologic and clinical profiles
Novel nonthienopyridine platelet P2Y12 receptor antago-
nists, including ticagrelor, cangrelor, and elinogrel, are also 
being investigated. These are direct and reversible P2Y12 
antagonists with various formulations but with rapid onsets 
and short durations of action. Among these, ticagrelor has 
come the furthest, having undergone a Phase 3 clinical 
trial.31 As a prototype drug from the novel cyclopentyl-
triazolopyrimidine class of antiplatelets, ticagrelor (previ-
ously known as AZD6140) is chemically distinct from the 
thienopyridines and can reversibly inhibit the P2Y12 ADP 
receptor. It is highly selective and very specific for the P2Y12 
receptor, and it exhibits a greater, more consistent IPA than 
clopidogrel.32 Like the thienopyridines, ticagrelor is also 
administered orally, but because of its direct action, ie, not 
requiring metabolic activation, ticagrelor has a rapid onset, 
peaking within 2–4 hours of dosing.33 The metabolism of 
ticagrelor yields an active molecule (AR-C124910XX) that 
has similar P2Y12-blocking activity as its parent molecule. 
Ticagrelor’s plasma half-life is approximately 12 hours, 
which corresponds to twice-daily dosing. In contrast to 
clopidogrel and prasugrel, which should be discontinued 
approximately 5 days before the restoration of normal 
platelet-mediated hemostasis, ticagrelor’s short duration of 
action and an offset of action in 1–2 days preclude the need 
for delaying surgical intervention, such as coronary artery 
bypass grafting (CABG). On the other hand, this potential 
advantage also carries the risk of increased thrombotic events 
if patients miss a ticagrelor dose.14,18,19 The pharmacologic 
properties of some currently used and investigational anti-
platelet drugs are shown in Table 1.
Several Phase 2 clinical trials have been conducted using 
ticagrelor, the first reversibly binding oral P2Y12 receptor 
antagonist (Table 2). In an initial Phase 2a parallel-group 
safety and efficacy trial (DISPERSE), 200 patients with 
atherosclerosis were randomized to receive either ticagrelor 
(doses of 50, 100, or 200 mg twice daily, or 400 mg once 
daily) or clopidogrel (75 mg once daily) for 28 days, in addi-
tion to 75–100 mg of aspirin per day. Measuring the IPA 
showed that the three higher doses of ticagrelor (ie, 100 and 
200 mg twice daily and 400 mg once daily) provide a nearly 
complete inhibition of ADP-induced platelet aggregation 
after the initial dosing. Although investigators write that 
in general ticagrelor was well tolerated, there was a higher 
incidence of bleeding with the three higher doses, mostly 
of mild to moderate severity, and there were also reports of 
dyspnea.36
This trial was followed by the Phase 2b Dose confIrma-
tion Study assessing anti-Platelet Effects of AZD6140 vs 
clopidogRel in non-ST-segment Elevation acute coronary 
syndromes (DISPERSE-2) trial.37 In this trial, 990 patients 
with non-ST-segment elevation ACS were randomized to 
receive any one of the following dosage: ticagrelor 90 mg 
twice daily, ticagrelor 180 mg twice daily, or clopidogrel 
300 mg loading dose plus 75 mg once daily for up to 12 
weeks. This study showed no difference in major bleeding but 
an increase in minor bleeding at the higher dose of ticagrelor, 
with encouraging – although not statistically significant – 
results on the secondary end point of MI.37 For the possible 
advantage of ticagrelor’s reversible inhibition, there was only 
a numerically lower rate of bleeding (again nonsignificant) in 
ticagrelor-treated patients undergoing CABG between 1 and 
5 days after stopping ticagrelor, which would be consistent 
with the recovery of platelet function. Another analysis of 
the DISPERSE-2 data compared the antiplatelet effects of 
ticagrelor with those of clopidogrel and assessed the effects 
of ticagrelor on clopidogrel-pretreated patients.39 It demon-
strated that ticagrelor treatment resulted in further IPA in Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Pharmacologic properties and adverse effects of a selection of antiplatelet agents
Drug Action Aggregation  
to ADP
Route of 
administration
Metabolism Time to  
peak effect
Offset of 
action
Adverse effects
Clopidogrel  
300 mg
iRR ∼30% Oral esterase inactivation 
and two-step hepatic 
CYP-dependent 
activation
∼4 hours ∼5 days Bleeding (major and 
minor), interpatient 
variability, and  
dyspnea in 
approximately  
8% of patients34
Prasugrel  
60 mg
iRR 75%–80% Oral esterase activation 
and one-step CYP- 
dependent activation 
(liver or gut)
1–2 hours  ∼5 days Bleeding (major and 
minor) and dyspnea in 
approximately  
5% of patients30
Ticagrelor R 75%–80% Oral None required 1–2 hours 1–2 days Bleeding, dyspnea in 
approximately  
14% of patients,  
and ventricular pauses31
Cangrelor  
4 μg/kg/min
R .90% intravenous None required Minutes 20 minutes Bleeding (minor) and 
dyspnea in 
approximately 
1% of patients35
elinogrel  
40 mg
R Oral/intravenous None required 20 minutes ∼1 day No increase in bleeding
SCH 530348 R (.90% to  
TRAP)
Oral None required with  
LD: hours; 
without  
LD: days
weeks No increase in bleeding
Abbreviations: ADP, adenosine diphosphate; CYP, cytochrome P450; iRR, irreversible; LD, loading dose; R, reversible; TRAP, thrombin receptor antagonist peptide.
patients already receiving clopidogrel, including those with 
the highest platelet aggregation response.
On the basis of previous dose-confirmation trials, the 
Phase 3 PLATO (PLATelet inhibition and patient Outcomes) 
trial was conducted to compare ticagrelor and clopidogrel 
with respect to their efficacy in preventing cardiovascular 
events and safety.31 In this trial, 18,624 patients with ACS 
(both with and without ST-segment elevation), in addition 
to the aspirin therapy, received loading doses of ticagrelor 
180 mg or clopidogrel 300 mg (with an additional 300 mg 
clopidogrel at PCI) and then ticagrelor 90 mg twice daily or 
clopidogrel 75 mg once daily for 6–12 months. As compared 
to treatment with clopidogrel, ticagrelor was found to 
significantly reduce the rate of death from vascular causes, 
MI, or stroke (primary end point: 11.7% vs 9.8%; P , 0.001), 
without an increase in the rate of overall major bleeding.31 
These findings are noteworthy in that ticagrelor is the first 
investigational antiplatelet to demonstrate a reduction in 
cardiovascular death when compared with clopidogrel in 
patients with ACS. Ticagrelor reduced the risk of cardio-
vascular events early on, and this benefit over clopidogrel 
increased over time. Among the subset of patients who 
received a stent during the study, a 38% RRR of definite 
stent thrombosis was achieved with ticagrelor (1.0% vs 1.6%; 
P = 0.003).40 Patients weighing less than the median weight 
for their sex, those who were not on lipid-lowering drugs at 
randomization, and those from North America were found 
to attain fewer benefits from ticagrelor treatment.31 Although 
there was no increased risk of CABG-related bleeding, the 
PLATO investigators did find an increase in the rate of 
non-procedure-related bleeding (clopidogrel 3.8% vs ticagre-
lor 4.5%; P = 0.03), including more instances of fatal intrac-
ranial bleeding but fewer instances of fatal bleeding of other 
types.31 The summation of major and minor bleeding events 
also showed an increase with ticagrelor when compared 
with clopidogrel (ticagrelor 16.1% vs clopidogrel 14.6%; 
P = 0.008).40 In addition to the bleeding tendency, in line with 
the findings of Phase 2 trials, ticagrelor was associated with 
more ventricular pauses in the first week (ticagrelor 5.8% vs 
clopidogrel 3.6%; P = 0.01), but not at day 30, and with more 
reports of dyspnea (ticagrelor 13.8% vs clopidogrel 7.8%; 
P , 0.001).31 The former occurred without clinical conse-
quences for the patient, whereas the latter was responsible 
for 1 in 100 ticagrelor-treated patients stopping treatment.41 
Thus, dyspnea was clinically limiting in around 1% of 
ticagrelor-treated patients. This rare but clinically meaning-
ful and recurring finding awaits authoritative assessment and 
explanation. Given the large database of the PLATO trial, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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analyses continue to be made of the findings. A subanalysis 
of patients with STEMI (PLATO STEMI) also showed that 
compared with clopidogrel treatment, ticagrelor treatment 
reduced cardiovascular events for up to a year (11.0% vs 
9.3%; P = 0.02), a difference driven mainly by a statisti-
cally significant reduction in MIs (6.1% vs 4.7%; P = 0.01), 
without an increase in major bleeding.42
In the meantime, results of further Phase 2 trials of 
ticagrelor were released. The ONSET/OFFSET study 
(n = 123) was designed to assess the rates of onset and offset 
of the antiplatelet effects of ticagrelor versus clopidogrel 
taken for 6 weeks by patients with stable CAD receiving 
aspirin therapy.38 Using the same dosing scheme as that used 
in PLATO trial, it showed that ticagrelor achieved faster 
onset (41% IPA vs 8% at 30 minutes; P , 0.0001), greater 
IPA, and faster offset in comparison with clopidogrel. The 
RESPOND trial, through a two-way crossover, investigated 
the antiplatelet effect of ticagrelor in 98 patients with stable 
CAD, which included both clopidogrel responders and 
clopidogrel nonresponders.43,44 The importance of this issue 
is reflected in reports estimating the frequency of clopidogrel 
nonresponders at about 10% and low responders at about 
20%.44 Among patients identified as clopidogrel responders, 
switching from clopidogrel to ticagrelor resulted in a mean 
IPA increase of 26%, whereas switching from ticagrelor to 
clopidogrel resulted in a mean IPA decrease of 24%.45 Thus, 
the RESPOND trial found that patients could be switched 
from ticagrelor treatment to clopidogrel treatment without 
the interruption of antiplatelet effect. It was concluded that 
clopidogrel nonresponders and responders exhibit superior 
platelet inhibition during ticagrelor therapy. However, the 
RESPOND trial findings also demonstrated that because of 
the variability of the clopidogrel response, identification of 
clopidogrel nonresponders is difficult.41 Finally, research has 
shown ticagrelor to produce platelet inhibition, regardless 
of the genotypic variations in the three genes that had been 
associated with the variability in platelet reactivity.39
All these trials underline the potential of ticagrelor to 
achieve a rapid and sustained antiplatelet effect, which 
could be reversed and could overcome nonresponsiveness 
and interpatient variability to clopidogrel, thus addressing 
the main limitations of clopidogrel therapy.3 Nonetheless, 
Table 2 Ticagrelor: results of clinical trials
Phase Clinical trial Patients Dosage Results
Phase 2 DiSPeRSe36 200 patients  
with atherosclerosis
Randomization to ticagrelor 
(doses of 50, 100, or 200 mg 
TD, or 400 mg OD) or 
clopidogrel (75 mg OD),  
on top of aspirin (75–100 mg OD),  
for 28 days
Ticagrelor TD produced a more rapid 
and greater iPA than clopidogrel  
(90% vs 60%)
DiSPeRSe-237 990 patients  
with non-ST-segment 
elevation ACS
Randomization to ticagrelor  
(90 or 180 mg TD) or  
clopidogrel (75 mg OD),  
on top of aspirin 
(75 and 100 mg OD),  
for up to 12 weeks
No difference was observed in the total 
bleeding rate between 90-mg  
ticagrelor-treated, 180-mg  
ticagrelor-treated, and clopidogrel-
treated groups (9.8%, 8.0%, and 8.1%, 
respectively)
ONSeT/OFFSeT38 123 patients  
with stable CAD
Randomization to ticagrelor  
(90 mg TD), clopidogrel  
(75 mg OD), or placebo,  
on top of aspirin (75–100 mg OD),  
for 6 weeks
Ticagrelor achieved more rapid and 
greater platelet inhibition than high-LD 
clopidogrel .50% iPA (98% vs 31%, 
P , 0.0001) and .70% iPA (90% vs 
16%, P , 0.0001) at 2-h post-LD; this 
was sustained during the maintenance 
phase and was faster in offset after 
drug discontinuation
Phase 3 PLATO31 18,624 patients  
with ACS
Randomization to LDs of 
ticagrelor (180 mg) or 
clopidogrel (300 mg; with an 
additional 300 mg clopidogrel at 
PCi), then ticagrelor (90 mg TD) 
or clopidogrel (75 mg OD), on 
top of aspirin (75–100 mg OD), 
for 6–12 months
Compared with clopidogrel treatment, 
ticagrelor treatment was found to 
significantly reduce the rate of death 
from vascular causes, Mi, or stroke 
(primary end point: 11.7% vs 9.8%, 
P , 0.001), without an increase in  
the rate of overall major bleeding
Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; iPA, inhibition of platelet aggregation; LD, loading dose; Mi, myocardial infarction; OD, once 
daily; PCi, percutaneous coronary intervention; TD, twice daily. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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its adverse effects such as dyspnea and bradycardia, its 
relationship with patient weight, and the lack of its benefit in 
North American patients require further investigation before 
ticagrelor may advance further toward a place in antiplatelet 
therapy guidelines.31
Other antiplatelet drugs in research  
and development and their clinical 
potential
Cangrelor, another novel reversible P2Y12 antagonist, is a 
chemically modified version of ticagrelor, which can be 
administered parenterally. It acts rapidly, producing profound 
platelet inhibition within 15 minutes of initiating infusion 
when compared with the 1- to 2-hour time frame for prasugrel 
and ticagrelor. This intravenous (iv) adenosine triphosphate 
analog has a plasma half-life of 5–9 minutes and is highly 
reversible, so the platelet function returns to the baseline 
level of activation 20 minutes after the discontinuation of 
cangrelor.14,46,47 Because of such a rapid offset, cangrelor 
was foreseen as a drug for the catheterization laboratory; 
like GP IIb/IIIa antagonists, it has to be started right before 
a PCI procedure and stopped immediately after it, while 
other antiplatelets would provide long-term protection 
from then onward.46,48 Phase 2 safety trials did not note 
any deaths or serious events attributed to cangrelor.46,47 
CHAMPION-PCI (A Clinical Trial Comparing Cangrelor 
to Clopidogrel in Subjects Who Require Percutaneous 
Coronary Intervention), a prospective Phase 3 trial of 9,000 
patients with unstable angina, MI, or ACS awaiting PCI, 
aimed to compare the efficacy of cangrelor with that of 
clopidogrel in subjects requiring PCI.49 On the other hand, 
the CHAMPION PLATFORM (A Clinical Trial Comparing 
Treatment With Cangrelor [in Combination With Usual 
Care] to Usual Care, in Subjects Who Require Percutaneous 
Coronary Intervention), a trial on 6400 patients requiring 
PCI, planned to test the potential superiority of cangrelor 
(combined with usual care) over the placebo, as measured by 
a composite of all-cause mortality, MI, and ischemia-driven 
revascularization.50 Both studies have been terminated due to 
insufficient evidence of cangrelor’s clinical efficacy.51
Although no Phase 3 data are available, another Phase 2 
study is in progress, with the purpose of demonstrating that 
patients receiving cangrelor infusion before CABG have an 
acceptable safety profile and can undergo surgery without 
excessive perioperative bleeding. This maintenance of 
platelet inihiBition with cangRelor after dIscontinuation of 
thienopyriDines in patients undergoing surGEry (BRIDGE) 
trial plans to follow up 220 patients undergoing nonemergent 
CABG, who had already received a thienopyridine antiplatelet 
drug, and foresees completion in July 2010.52
Elinogrel (also known as PRT060128), the next addition 
to the reversible, direct-acting nonthienopyridine P2Y12 
receptor antagonists, is unique in that it can be administered 
both orally and intravenously.53 This allows for an immedi-
ate and reversible effect of high-level platelet inhibition, 
preferable in acute conditions, and an easy transition to 
reversible platelet inhibition in the chronic setting.54 Its 
simplified administration covers the full spectrum of care, 
from acute onset to chronic care, and its reversibility allows 
for surgery without significant delay. Thus far, elinogrel has 
undergone Phase 2A ERASE MI (Early Rapid ReversAl of 
platelet thromboSis with intravenous Elinogrel before PCI 
to optimize reperfusion in acute Myocardial Infarction) pilot 
trial.55 In this safety and efficacy dose-escalation trial, 70 
patients with STEMI undergoing primary PCI were random-
ized to an iv bolus of placebo versus elinogrel (at doses of 
10, 20, 40, and 60 mg), in addition to standard treatment, 
prior to angiography. There appeared to be no difference 
between the placebo and elinogrel (at doses of 10, 20, 40, 
and 60 mg) with respect to the incidence of the infrequent 
bleeding events. Neither were there any differences in serious 
adverse events, laboratory values, and corrected thrombolysis 
in MI (TIMI) frame count, nor was any ST resolution between 
elinogrel and placebo.56 Although the dose-confirmation 
phase was not started, as the trial was prematurely terminated 
for administrative reasons, the ERASE MI findings provide 
preliminary support for the use of elinogrel as an adjunctive 
therapy in primary PCI for STEMI. Meanwhile, the results 
of elinogrel’s Phase 2b INNOVATE-PCI (A randomized, 
double-blind, active-controlled trial to evaluate intravenous 
and oral PRT060128, a selective and reversible P2Y12 
inhibitor, vs clopidogrel, as a novel antiplatelet therapy in 
patients undergoing nonurgent PCI) are awaited. In this trial, 
800 patients, who were randomized to the clopidogrel control 
or to one of three experimental regimens of elinogrel (80-mg 
bolus administered intravenously prior to PCI, followed by 
twice-daily oral dosing of 50, 100, or 150 mg), are being 
studied prior to nonurgent PCI and in the 60-day chronic 
treatment phase.57 INNOVATE-PCI is designed not to exam-
ine a prespecified endpoint, but rather to explore a number 
of analyses to understand the clinical efficacy, biological 
activity, tolerability, and safety of elinogrel.
Two more investigational nonthienopyridine P2Y12 
antagonists, BX 667 and its active metabolite BX 048, are in 
the early stages of clinical development. Thus far, they have 
undergone animal trials, performed on rat and dog models, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and pharmacodynamic and pharmacokinetic studies.58,59 They 
are hoped to be useful in safely decreasing cardiovascular 
events in patients undergoing PCI.
Besides the great variety of new ADP receptor antago-
nists, a new class of antiplatelet agents targeting the potent 
thrombin-induced activation of platelets is emerging. The 
first member of these thrombin receptor antagonists (TRAs) 
SCH 530348 and the second member E5555 antagonize the 
platelet PAR1. This receptor found in platelets and smooth 
muscle cells possesses a high affinity to thrombin and 
via coupling to Gp/Gi proteins, mediates the activation of 
these cells by thrombin.11 The safety and efficacy of SCH 
530348 have already been tested in various Phase 2 trials, 
including the TRA-PCI study, and two Phase 3 trials are 
presently being conducted.60 The TRA 2(°)P-TIMI 50 trial 
(Thrombin Receptor Antagonist in Secondary Prevention 
of Atherothrombotic Ischemic Events) on approximately 
19,500 patients with atherosclerotic disease (prior MI or 
stroke or with existing peripheral arterial disease), in the 
course of at least 1-year follow-up, compares the safety 
and efficacy of SCH 530348 against the existing standard 
of care (aspirin and clopidogrel) in preventing MI, stroke, 
and urgent coronary revascularization and in assessing its 
bleeding risk.61 On the other hand, the TRA-CER (Thrombin 
Receptor Antagonist for Clinical Event Reduction in Acute 
Coronary Syndrome) study is designed to compare the 
efficacy of a combination of SCH 530348 and the existing 
standard of care (eg, aspirin and clopidogrel) with that of the 
existing standard of care alone in preventing MI and stroke 
in patients with ACS.62 By following up approximately 
10,000 patients with non-STEMI for a minimum of 1 year, 
the study will also assess the bleeding risk of both treatment 
variants (ie, a combination of SCH 530348 and the existing 
standard of care, and the existing standard of care alone). The 
results of these large-scale trials, planned to be completed 
in September 2010 and July 2011, respectively, are eagerly 
awaited. The other member of the TRA group, E5555, is 
currently being evaluated in two Phase 2 trials, LANCE-
LOT (Lessons from Antagonizing the Cellular Effects Of 
Thrombin) trials 201 and 202.63,64 In each trial, approximately 
600 patients with CAD will be followed up in order to assess 
E5555’s safety and efficacy in inhibiting platelet aggregation 
and endovascular inflammatory processes and to measure the 
incidence of major adverse cardiovascular events.
There are also new up-and-coming drugs interfer-
ing with the thromboxane pathway, upon which aspirin 
acts. NCX 4016 (nitroaspirin) is a nitric oxide-releasing 
aspirin that combines all the benefits of aspirin with those 
of nitric oxide.65 NCX 4016, with its antithrombotic, 
antiatherogenic, and vasodilatory properties, is known to be 
strongly cardioprotective. Also being evaluated is S18886 
(terutroban), a TXA2 receptor inhibitor, currently undergo-
ing the PERFORM (Prevention of Cerebrovascular and 
Cardiovascular Events of Ischemic Origin with Terutroban 
in Patients with a History of Ischemic Stroke or Transient 
Ischemic Attack) study in patients with recent stroke or 
transient ischemic attack.12,66 This Phase 2 trial is designed to 
compare this specific TP receptor antagonist with aspirin in 
reducing the incidence of cerebrovascular and cardiovascular 
events.67 Terutroban may be of particular interest because 
studies in a murine model have shown the inhibition of the 
TXA2 receptor to decrease atherosclerosis progression.68 
Moreover, novel antithrombotic compounds discovered 
inhibit thrombin while antagonizing GP IIb/IIIa. The future 
of such dual-function pharmaceuticals in CVDs remains to be 
seen. The same is true for PR-15, the investigational platelet 
GP VI adhesion antagonist, and the drugs targeting platelet 
endothelial aggregation receptor 1.69,70
Conclusions and future research
Given the pathologic process of intraarterial platelet activation 
underlying CVDs, it is clear that antiplatelet therapeutic 
options are needed for treating CVDs and preventing their 
complications. Significant progress has already been made in 
the field of antiplatelet therapy, as it aims to inhibit platelet 
aggregation and acute thrombus formation, while preventing 
intolerable bleeding. There exists a growing spectrum of 
drugs modifying these pathologic processes, which continues 
to expand in the hopes of overcoming the limitations of 
current standard treatment. Novel platelet-inhibiting drugs 
act through diverse mechanisms, mostly interfering with 
ADP-induced platelet aggregation, but also targeting the 
TXA2 pathway and thrombin-induced signaling.11–13 In con-
trast to the available GP IIb/IIIa antagonists, which block the 
final common pathway of platelet aggregation, the possibility 
emerges of disrupting initial mechanisms of adhesion by 
targeting GP IV , a key receptor for collagen.69 As combina-
tion regimens are often required to achieve sufficient platelet 
inhibition, new approaches to old mechanisms are explored, 
such as the combination of nitric oxide and aspirin in the 
investigational agent NCX 4016.65
As our understanding of the complex molecular and 
genetic bases of atherothrombotic disease expands, modern 
medicine moves toward more individualized patient treatment. 
The growing stock of antiplatelet drugs at our disposal 
can help us treat the full spectrum of and various stages Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in atherothrombotic manifestations of atherosclerosis while 
catering to the needs and risk factors of specific patients. This is 
slowly becoming a reality, for example, prasugrel is especially 
useful in patients with high risk of ischemic events as in those 
with diabetes mellitus.19,28,29 Ticagrelor is possibly a useful 
agent before CABG, as its more potent platelet inhibition did 
not increase CABG-related bleeding, although its side effects 
such as dyspnea and ventricular pauses could additionally 
limit its patient base.31 On the other hand, both prasugrel 
and ticagrelor seem less liable to decreased patient response 
because of genetic polymorphism of receptors and enzymes; 
thus, these agents potentially provide platelet inhibition in 
patients who are clopidogrel nonresponders.22,38,39 Elinogrel, 
even though it has not entered Phase 3 trials, is encouraging 
because of its simplified administration scheme, allowing for 
a smooth transition from acute to chronic treatment.
Progress with respect to the potency of platelet inhibition 
has also brought increased bleeding tendency. To shift the 
balance from causing excess bleeding toward preventing 
vascular occlusion, dose adjustments are necessary in 
low-weight patients for drugs such as prasugrel and 
ticagrelor.29,31 As age is another factor found to increase bleed-
ing, elderly patients still await a registered drug to address 
their needs. In contrast to the studies on clopidogrel and pra-
sugrel, ticagrelor, besides its stronger platelet inhibition, did 
not increase the risk of major bleeding; thus, it may become 
an antiplatelet option for older patients, although it may not be 
possible for those with respiratory problems or symptomatic 
bradycardia.30,31,34 Also, with regard to bleeding, the group of 
thrombin receptor inhibitors is particularly promising, as it 
is hypothesized that the pathway they block may play a role 
only in pathologic thrombosis, leaving physiologic hemosta-
sis intact. Such an advantage with respect to bleeding risk is 
also evidenced by animal studies, showing a decrease in the 
progression of atherosclerosis.11,68
Dyspnea, another clinically relevant adverse effect, 
was found to occur in up to 5%, 8%, 14%, and 1% of 
patients receiving prasugrel, clopidogrel, ticagrelor, and 
cangrelor, respectively.30,31,34,35 An analysis by Serebruany 
et al71 considered the pathophysiology of the respiratory 
distress and platelet inhibition. The authors found dyspnea 
to be a very rare complication, mostly caused by underlying 
diseases – cardiac, respiratory, or allergic – and concomitant 
medications (high-dose angiotensin-converting enzyme 
inhibitors) rather than by the antiplatelet therapy itself. It was 
suggested that especially reversible agents (like ticagrelor) 
could lead to the development of mild, asymptomatic 
thrombotic thrombocytopenic purpura, fluid retention, 
and dyspnea. Another proposed hypothesis is that certain 
antiplatelets may be metabolized to adenosine (ticagrelor’s 
molecular structure has components almost identical to those 
of adenosine), which is an established bronchoprovocator. 
Although the true reason for the statistically significant 
increase in dyspnea – particularly with ticagrelor – remains to 
be uncovered, it is clear that further studies should follow up 
this finding to assess its clinical significance in the long-term 
care of patients with atherothrombotic disease.71
In summary, the abundant novel antiplatelet agents, with 
their higher potencies, higher platelet specificities, various 
drug formulations, possible reversibility, less variability in 
patient response, more rapid onsets and offsets of action, 
and short time to peak, along with their attempts for better 
safety, hold high potential. Some are in advanced stages of 
development with assuring outcomes, and further clinical 
evaluation is needed to determine which of them will find a 
place within standard antiplatelet therapy.
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